Discovery and pharmacological profile of new 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-c]quinoline derivatives as selective serotonin 4 receptor ligands

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9446-9466

  Furlotti, Guido ^a   Alisi, Maria Alessandra ^a   Apicella, Claudia ^a   Capezzone De Joannon, Alessandra ^a   Cazzolla, Nicola ^a   Costi, Roberta ^b   Cuzzucoli Crucitti, Giuliana ^b   Garrone, Beatrice ^a   Iacovo, Alberto ^b   Magarò, Gabriele ^a   Mangano, Giorgina ^a   Miele, Gaetano ^b   Ombrato, Rosella ^a   Pescatori, Luca ^b   Polenzani, Lorenzo ^a   Rosi, Federica ^b   Vitiello, Marco ^a   Di Santo, Roberto ^b  

^a Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL N [[1 (2 PHENYLETHYL) 4 PIPERIDINYL]METHYL] 1H INDAZOLE 3 CARBOXAMIDE; 1 ISOPROPYL N [[1 (PHENYLMETHYL) 4 PIPERIDINYL]METHYL] 1H INDAZOLE 3 CARBOXAMIDE; 1 METHYL N (4 PIPERIDINYLMETHYL) 1H INDAZOLE 3 CARBOXAMIDE; 1 SEC BUTYL N [[1 (2 PHENYLETHYL) 4 PIPERIDINYL]METHYL] 1H INDAZOLE 3 CARBOXAMIDE; 1H INDAZOLE 3 CARBOXAMIDE; 2 ISOPROPYL 2H PYRROLO[3,4 C]QUINOLIN 4(5H) ONE; 2 METHYL 2H PYRROLO[3,4 C]QUINOLIN 4(5H) ONE; 2 METHYL 4 (4 PIPERIDINYLMETHOXY) 2H PYRROLO[3,4 C]QUINOLINE; 2H PYRROLO[3,4 C]QUINOLINE DERIVATIVE; 4 [(4 PIPERIDINYL)METHOXY] 2H PYRROLO[3,4 C]QUINOLINE DERIVATIVE; INDAZOLE DERIVATIVE; N [(1 BUTYL 4 PIPERIDINYL)METHYL] 1(2)METHYLINDAZOLE 3 CARBOXAMIDE; N [(1 BUTYL 4 PIPERIDINYL)METHYL] 2 METHYL 2H INDAZOLE 3 CARBOXAMIDE; N [(1 BUTYL 4 PIPERIDINYL)METHYL] 5 CHLORO 1 METHYL 1H INDAZOLE 3 CARBOXAMIDE; N [(4 PIPERIDINYL)METHYL] 1H INDAZOLE 3 CARBOXAMIDE; N [[1 (2 PHENYLETHYL) 4 PIPERIDINYL]METHYL] 1H INDAZOLE 3 CARBOXAMIDE; POTASSIUM CHANNEL HERG; QUINOLINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 4 ANTAGONIST; SEROTONIN 4 RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; LIGAND BINDING; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTATIONAL BIOLOGY; DOGS; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LIGANDS; MACACA FASCICULARIS; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NOCICEPTION; PROTEIN BINDING; QUINOLINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SEROTONIN, 5-HT4; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 84870052595     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300573d     Document Type: Article

References (54)

1. Hoyer, D.; Martin, G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome Neuropharmacology 1997, 36, 419-428
2. Humphrey, P. P. A. The characterization and classification of neurotransmitter receptors. Ann. N.Y. Acad. Sci. 1997, 812, 1-13.
3. Nichols, D. E.; Nichols, C. D. Serotonin receptors Chem. Rev. 2008, 108 (5) 1614-1641
4. 4 receptors Curr. Drug. Targets: CNS Neurol. Disord. 2004, 3, 39-51
5. 4 receptors: history, molecular pharmacology and brain functions Neuropharmacaology 2008, 55, 922-931
6. 4 receptors Trends Pharmacol. Sci. 1995, 16, 391-398
7. 4 receptors FASEB J. 1996, 10, 1398-1407
8. 4 receptors ligands: application and new prospects J. Med. Chem. 2003, 46 (3) 319-344
9. 4 receptor antagonists Med. Res. Rev. 1997, 17 (2) 163-214
10. Van Outryve, M.; Milo, R.; Toussaint, J.; Van Eeghem, P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride J. Clin. Gastroenterol. 1991, 13 (1) 49-57
11. 4 receptor agonist, in a model of slow colonic transit Clin. Pharmacol. Ther. 1997, 62 (5) 546-55
12. 4 agonist, prucalopride, in healthy humans Gut 1999, 44 (5) 682-686
13. 4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure Eur. J. Heart Failure 2009, 11 (8) 771-778
14. 4 binding sites J. Comput.-Aided Mol. Des. 1997, 11, 589-599
15. López-Rodriguez, M. L; Benhamú, B.; Morcillo, M. J.; Murcia, M.; Viso, A.; Campillo, M.; Pardob, L. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions Curr. Top. Med. Chem. 2002, 2 (6) 625-641
16. 4 receptor J. Chem. Inf. Comput. Sci. 2002, 42 (2) 962-967
17. Ghelardini, C.; Galeotti, N.; Casamenti, F.; Malmberg-Aiello, P.; Pepeu, G.; Gualtieri, F.; Bartolini, A. Central cholinergic antinociception induced by 5HT4 agonists: BIMU1 and BIMU8 Life Sci. 1996, 58 (25) 2297-2309
18. Doak, G. J.; Sawynok, J. Formalin-induced nociceptive behaviour and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes Neuroscience 1997, 80 (3) 939-949
19. 3 receptors Brain Res. 1998, 788, 20-24
20. Muller-Lissner, S. A.; Fumagalli, I.; Bardhan, K. D.; Pace, F.; Pecher, E.; Nault, B.; Ruegg, P. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment. Pharmacol. Ther. 2001, 15, 1655-1666
21. Hinschberger, A.; Butt, S.; Lelong, V.; Boulouard, M.; Dumuis, A.; Dauphin, F.; Bureau, R.; Pfeiffer, B.; Renard, P.; Rault, S. New benzo[ h ][1,6]naphthyridine and azepino[3,2- c ]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization J. Med. Chem. 2003, 46, 138-147
22. Lemaitre, S.; Lepailleur, A.; Bureau, R.; Butt-Gueulle, S.; Lelong-Boulouard, V.; Duchatelle, P.; Boulouard, M.; Dumuis, A.; Daveu, C.; Lezoualc'h, F.; Pfeiffer, B.; Dauphin, F.; Rault, S. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines Bioorg. Med. Chem. 2009, 17, 2607-2622
23. De Maeyer, J. H.; Lefebvre, R. A.; Schuurkes, J. A. 5-HT4 receptor agonists: similar but not the same Neurogastroenterol. Motil. 2008, 20, 99-112
24. 4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities J. Pharmacol. Sci. 2007, 105, 207-210
25. Tonini, M.; De Ponti, F.; Di Nucci, A.; Crema, F. Review article: cardiac adverse effects of gastrointestinal prokinetics Aliment. Pharmacol. Ther. 1999, 13, 1585-1591
26. 2 receptors Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 11-26
27. Trudeau, M. C.; Warmke, J. W.; Ganetzky, B.; Robertson, G. A. HERG, a human inward rectifier in the voltage-gated potassium channel family Science 1995, 269 (5220) 92-95
28. Wysowski, D. K.; Corken, A.; Gallo-Torres, H.; Talarico, L.; Rodriguez, E. M. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions Am. J. Gastroenterol. 2001, 96, 1698-1703
29. Fermini, B.; Fossa, A. A. The impact of drug-induced QT interval prolongation on drug discovery and development Nat. Rev. Drug Discovery 2003, 2 (6) 439-447
30. Schaus, J. M.; Thompson, D. C.; Bloomquist, W. E.; Susemichel, A. D.; Calligaro, D. O.; Cohen, M. L. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives J. Med. Chem. 1998, 41, 1943-1955
31. 4 receptor antagonist amide with oral activity J. Med. Chem. 1995, 38, 4760-4763
32. Alisi, A.; Brufani, M.; Cazzolla, N.; Giannangeli, M.; Pinza, M. Preparation of indazoleamide compounds as serotoninergic agents. PCT Int. Appl. WO 9846589, 1998.
33. Xie, W.; Herbert, B.; Schumacher, R.; Nguyen, T. M.; Ma, J.; Gauss, C. M.; Tehim, A. Preparation of quinuclidine indazole, benzothiazole, benzisothiazole and benzisoxazoles as ligands for the α7 nicotinic acetylcholine receptor. PCT Int. Appl. WO 2005092890, 2005.
34. Inoue, T.; Watanabe, S.; Yamagishi, T.; Arano, Y.; Morita, M.; Shimada, K. Preparation of pyridinylcarboxamide derivatives and analogs for use as calcium or sodium channel blockers. PCT Int. Appl. WO 2010137351, 2010.
35. Foreman, E. L.; McElvain, S. M. Reaction of organic halides with piperidine. V. Negatively substituted ethyl bromides J. Am. Chem. Soc. 1940, 62, 1435-1438
36. Di Santo, R.; Costi, R.; Forte, M.; Galeffi, C. A general, versatile synthesis of 2 H -pyrrolo[3,4- c ]quinolines via tosylmethylisocyanide reaction ARKIVOC 2004, v) 181-195
37. Diaz, P.; Millois Barbuis, C. Preparation of bi-aromatic compounds, particularly 4-[(3-aminocarbonylhydrazono-2-oxo-2,3-dihydro-1 H -indol-5-yl)sulfanylalkyl]benzoic acid derivatives, as PPAR modulators, and their use in cosmetic and pharmaceutical compositions. PCT Int. Appl. WO 2006063863, 2006.
38. Yang, D.; Goldstin, B.; Moormann, A. E.; Flynn, D. L.; Gullikson, G. W. SC-53606, a potent and selective antagonist of 5-hydroxytryptamine 4 receptors in isolated rat esophageal tunica muscularis mucosae J. Pharmacol. Exp. Ther. 1993, 266, 1339-1347
39. Mialet, J.; Dahmoune, Y.; Lezoualc'h, F.; Berque-Bestel, I.; Eftekhari, P.; Hoebeke, J.; Sicsic, S.; Langlois, M.; Fishmeister, R. Exploration of the ligand binding site of the human 5-HT4 receptor by site-directed mutagenesis and molecular modeling Br. J. Pharmacol. 2000, 130, 527-538
40. 4 receptor binding site: exploration of a hydrophobic pocket Br. J. Pharmacol. 2004, 143, 361-370
41. Bojarski, A. J. Pharmacophore models for metabotropic 5-HT receptor ligands Curr. Top. Med. Chem. 2006, 6, 2005-2026
42. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
43. Zhu, B. Y.; Jia, Z. J.; Zhang, P.; Su, T.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi, V.; Eddy, P.; Sinha, U.; Scarborough, R. M.; Song, Y. Inhibitory effect of carboxylic acid group on hERG binding Bioorg. Med. Chem. Lett. 2006, 16, 5507-5512
44. Brudeli, B.; Moltzau, L. R.; Andressen, K. W.; Krobert, K. A.; Klaveness, J.; Levy, F. O. Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists Bioorg. Med. Chem. Lett. 2010, 18, 8600-8613
45. Uno, Y.; Fujino, H.; Kito, G.; Kamataki, T.; Nagata, R. CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone Mol. Pharmacol. 2006, 79, 477-486
46. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsomes Drug Metab. Dispos. 1999, 27 (11) 1350-1359
47. Eddy, N. B.; Leimbach, D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines J. Pharmacol. Exp. Ther. 1953, 107, 385-393
48. Dubuisson, D.; Dennis, S. G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats Pain 1977, 4, 161-174
49. Irwin, S. Comprehensive observational assessment: a systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse Pychopharmacologica 1968, 13, 222-257
50. Roux, S.; Sable, E.; Porsolt, R. D. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effect on behaviour and physiological function. In Current Protocols in Pharmacology; Enna, S. J.; Williams, M., Eds.; Wiley: New York, 2004; Suppl. 27, Unit 10.10, pp 1-23.
51. Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. A. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput.-Aided Mol. Des. 2006, 20 (10-11) 647-671
52. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks; Glide, J. L. A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening J. Med. Chem. 2004, 47 (7) 1750-1759
53. Woolfe, G.; Mac Donald, A. D. The evaluation of the analgesic action of pethidine hydrochloride (DEMEROL) J. Pharmacol. Exp. Ther. 1944, 80, 300-307
54. Colucci, M.; Maione, F.; Bonito, M. C.; Piscopo, A.; Di Giannuario, A.; Pieretti, S. New insights of dimethyl sulphoxide effects (DMSO) on experimental in vivo models of nociception and inflammation Pharmacol. Res. 2008, 57, 419-425